Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques

被引:150
作者
Tsai, CC
Emau, P
Jiang, YH
Tian, BP
Morton, WR
Gustafson, KR
Boyd, MR
机构
[1] Univ Washington, Natl Primate Res Ctr, Seattle, WA 98195 USA
[2] NCI, Mol Targets Dev Program, Ctr Canc Res, Frederick, MD 21702 USA
[3] Univ S Alabama, Coll Med, Canc Res Inst, Mobile, AL 36608 USA
关键词
D O I
10.1089/088922203322230897
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cyanovirin-N (CV-N), an 11-kDa cyanobacterial protein, potently inactivates diverse strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV) and also prevents virus-to-cell fusion, virus entry, and infection of cells in vitro. These properties make CV-N an attractive candidate for use as a topical microbicide to prevent the sexual transmission of HIV. We evaluated the efficacy of gel-formulated, recombinant CV-N gel as a topical microbicide in male macaques (Macaca fascicularis) that were rectally challenged with a chimeric SIV/HIV-1 virus known as SHIV89.6P. All of the untreated macaques were infected and experienced CD4(+) T cell depletion. In contrast, none of the macaques that received either 1 % or 2 % CV-N gel showed evidence of SHIV89.6P infection. Neither CV-N nor placebo gels produced Any adverse effects in any macaque following the rectal application. These results indicate that CV-N gel As a topical microbicide can prevent rectal transmission of SHIV in macaques. These studies encouraged clinical evaluation of CV-N as a topical microbicide to prevent sexual transmisision of HIV in humans.
引用
收藏
页码:535 / 541
页数:7
相关论文
共 24 条
[1]   Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development [J].
Boyd, MR ;
Gustafson, KR ;
McMahon, JB ;
Shoemaker, RH ;
OKeefe, BR ;
Mori, T ;
Gulakowski, RJ ;
Wu, L ;
Rivera, MI ;
Laurencot, CM ;
Currens, MJ ;
Cardellina, JH ;
Buckheit, RW ;
Nara, PL ;
Pannell, LK ;
Sowder, RC ;
Henderson, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1521-1530
[2]  
Dailey P. J., 1995, Journal of Medical Primatology, V24, P209
[3]   Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses [J].
Dey, B ;
Lerner, DL ;
Lusso, P ;
Boyd, MR ;
Elder, JH ;
Berger, EA .
JOURNAL OF VIROLOGY, 2000, 74 (10) :4562-4569
[4]  
Gross M, 2000, J ACQ IMMUN DEF SYND, V24, P393, DOI 10.1097/00126334-200008010-00015
[5]   Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs [J].
Harouse, JM ;
Gettie, A ;
Tan, RCH ;
Blanchard, J ;
Cheng-Mayer, C .
SCIENCE, 1999, 284 (5415) :816-819
[6]   Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIVSF162P3 [J].
Harouse, JM ;
Gettie, A ;
Eshetu, T ;
Tan, RCH ;
Bohm, R ;
Blanchard, J ;
Baskin, G ;
Cheng-Mayer, C .
JOURNAL OF VIROLOGY, 2001, 75 (04) :1990-1995
[7]   Chimeric simian human immunodeficiency virus that causes progressive loss of CD4(+) T cells and AIDS in pig-tailed macaques [J].
Joag, SV ;
Li, Z ;
Foresman, L ;
Stephens, EB ;
Zhao, LJ ;
Adany, I ;
Pinson, DM ;
McClure, HM ;
Narayan, O .
JOURNAL OF VIROLOGY, 1996, 70 (05) :3189-3197
[8]  
*JOINT UN PROGR HI, 2001, AIDS EP UPD
[9]   AIDS treatment advances and behavioral prevention setbacks: Preliminary assessment of reduced perceived threat of HIV-AIDS [J].
Kalichman, SC ;
Nachimson, D ;
Cherry, C ;
Williams, E .
HEALTH PSYCHOLOGY, 1998, 17 (06) :546-550
[10]  
LEVY JA, 1998, HIV PATHOGENESIS AID, P28